Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1)
OVERVIEW
Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1) is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Mar 03 - 07, 2019 at Beaver Run Resort & Conference Center, Breckenridge, Colorado, United States of America.
Course Description :
Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. The unique opportunities it offers in terms of discovery of novel biology and first-in-class therapeutics are matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the meeting will be to share information/processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: Chemical biology advances and case studies in Target Identification; Case studies of recently advanced clinical candidates and approved drugs; Functional genomics and systems biology advances and case studies; Project prosecution: lessons learned from lead optimization and pre-clinical development; Complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 edition. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies – this meeting can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories - newly approved drugs and late stage clinical candidates - along with key lessons and best practices to inform future PDD projects.
Additional details will be posted as soon as they are available.
Course Description :
Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. The unique opportunities it offers in terms of discovery of novel biology and first-in-class therapeutics are matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the meeting will be to share information/processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: Chemical biology advances and case studies in Target Identification; Case studies of recently advanced clinical candidates and approved drugs; Functional genomics and systems biology advances and case studies; Project prosecution: lessons learned from lead optimization and pre-clinical development; Complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 edition. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies – this meeting can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories - newly approved drugs and late stage clinical candidates - along with key lessons and best practices to inform future PDD projects.
Additional details will be posted as soon as they are available.
KEY DATES
03 Mar, 2019
Event Start Date
07 Mar, 2019
Event End Date
SPECIALITIES
Clinical PharmacologyResearch and Clinical ResearchSUGGESTED HOTELS
CONFERENCE VENUE
Beaver Run Resort & Conference CenterRELATED CONFERENCES & LIVE WEBINARS
Quick Links